Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway

BACKGROUND: Cisplatin-based chemotherapy is mainstay treatment in urinary bladder cancer (UBC). However, tumor recurrence frequently occurs with the acquisition of cisplatin resistance. We explored the potential effect of a polyherbal preparation, Zyflamend, on UBC cells resistant to cisplatin treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Yanshi, Yang, Lin, Li, Junzun, Yan, Yilin, Jiang, Qinghui, Shen, Lan, Yang, Shuai, Shen, Bing, Huang, Ruimin, Yan, Jun, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072829/
https://www.ncbi.nlm.nih.gov/pubmed/30104883
http://dx.doi.org/10.2147/OTT.S162255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072829/
https://www.ncbi.nlm.nih.gov/pubmed/30104883
http://dx.doi.org/10.2147/OTT.S162255

Ejemplares similares